INKT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.2M
+11.6%
2.9M
+6.5%
2.7M
-15.0%
3.2M
-21.4%
4.1M
R&D
1.9M
+56.7%
1.2M
-20.4%
1.5M
+32.4%
1.1M
-37.8%
1.8M
SG&A
1.3M
-20.7%
1.7M
-4.9%
1.8M
-4.5%
1.8M
-0.1%
1.8M
Operating Income
-3216894
-11.6%
-2881787
-6.5%
-2705459
+15.0%
-3183594
+21.4%
-4052396
EBITDA
-3180830
-11.8%
-2845721
-6.7%
-2666896
+15.1%
-3139940
+21.6%
-4003633
Net Income
-3128201
-14.1%
-2742368
-5.4%
-2602103
+9.9%
-2887709
+31.9%
-4237751
EPS (Basic)
$-0.62
-8.8%
$-0.57
-3.6%
$-0.55
+15.4%
$-0.65
+38.7%
$-1.06
EPS (Diluted)
$-0.62
-8.8%
$-0.57
-3.6%
$-0.55
+15.4%
$-0.65
+38.7%
$-1.06
Shares (Diluted)
5.0M
+4.7%
4.8M
+2.3%
4.7M
+5.6%
4.4M
+11.6%
4.0M
MiNK Therapeutics (INKT) โ€” Financials